Hypolipidaemic Agents in the Treatment of Xanthomata
Animal studies (Kodama et al. 1981) and the resolution of xanthomata in many hyperlipidaemic patients after plasma lipid reduction (Hessel et al. 1976) have confirmed that the association between plasma lipids and xanthoma formation is causal. Accordingly, the treatment of hyperlipidaemia is an important component of the management of xanthomatous patients. Not all types of hyperlipidaemia produce xanthomata, and the nature of the lesions varies according to the lipoprotein class (Hessel et al. 1976). The lipoprotein patterns found in association with different forms of xanthomata are presented in Table 1 and the causes in Table 2 (Lewis 1976).
KeywordsGlycogen Storage Disease Familial Hypercholesterolaemia Familial Combine Hyperlipidaemia Hyperlipidaemic Patient Plasma Lipid Reduction
Unable to display preview. Download preview PDF.
- Barber MJ, Gilmour FR, Mueller TM, Zipes DP (1981) Electrophysiological effects of probucol on monkey ventricle. Circulation 64:IV–123Google Scholar
- Lewis B (1976) The hyperlipidaemias. Blackwell, OxfordGoogle Scholar
- Miller NE, Mjos OD, Oliver MF (1976) Effects of p-chlorophenoxyisobutyrate on free fatty acid mobilization from canine subcutaneous adipose tissue in situ. Clin Sci 51:107–110Google Scholar
- Noseda G, Lewis B, Paoletti R (1980) Diet and drugs in atherosclerosis. Raven, New YorkGoogle Scholar
- WHO (1980) WHO cooperative trial on primary prevention of ischaemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2:379–385Google Scholar